Past, Present, and Future of Targeting Ras for Cancer Therapies

Author(s): Zhi Tan, Shuxing Zhang

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 16 , Issue 5 , 2016

Become EABM
Become Reviewer
Call for Editor


For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers. However, targeting this oncogene has been challenging and no Ras inhibitors are on the market to date. Lately several candidates targeting the downstream pathways of Ras signaling, including PI3K and Raf, were approved for cancer treatment. However, they do not present promising therapeutic effects on patients harboring Ras mutations. Recently, a variety of compounds have been reported to impair the activity of Ras, and these exciting discoveries reignite the hope for development of novel drugs targeting mut-Ras. In this article, we will review the progress made in this field and the current state-of-the-art technologies to develop Ras inhibitors. Also we will discuss the future direction of targeting Ras.

Keywords: Cancer therapy, Drug discovery, GTPase, Mutant KRas, Small molecule inhibitor, Targeting Ras.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [345 - 357]
Pages: 13
DOI: 10.2174/1389557515666151001154111
Price: $65

Article Metrics

PDF: 85
PRC: 2